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Abstract  
Purpose: Potentially inappropriate prescribing (PIP) is common in older people and can 
result in increased morbidity, adverse drug events and hospitalisations. This study tested 
the effectiveness of a multifaceted intervention in reducing PIP in primary care. 
Methods: A cluster randomised controlled trial (RCT) was conducted with 21 GP practices 
and 196 patients with PIP. Intervention participants received a complex multi-faceted 
intervention incorporating academic detailing, medicines review with web-based 
pharmaceutical treatment algorithms that provide recommended alternative treatment 
options, and tailored patient information leaflets. Control practices delivered usual care and 
received simple, patient-level PIP feedback. Primary outcomes were the proportion of 
patients with PIP and the mean number of potentially inappropriate prescriptions. 
Intention-to-treat analysis using random effects regression was used. 
Results All practices and 190 patients were followed. Upon intervention completion, 
patients in the intervention group had significantly lower odds of having PIP than patients in 
the control group (adjusted odds ratio (OR) 0.32, 95% confidence interval (CI) 0.15 to 0.70, 
P=0.02). The mean number of PIP drugs in intervention was 0.70, compared to 1.18 in 
control (P=0.02). The intervention group was almost a third less likely than control to have 
PIP drugs at intervention completion, but this was not significant (incidence rate ratio 0.71, 
95% CI 0.50 to 1.02, P=0.49). The intervention was effective in reducing proton pump 
inhibitor prescribing (adjusted OR 0.30, 95% CI 0.14 to 0.68, P=0.04).  
Conclusions The OPTI-SCRIPT intervention incorporating academic detailing with a 
pharmacist and medicines’ review with web-based pharmaceutical treatment algorithms, 
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was effective in reducing PIP, particularly in modifying prescribing of proton pump 
inhibitors, the most commonly occurring PIP nationally. 
Trial Registration: Current controlled trials ISRCTN41694007 
 
Key words: randomised controlled trial, potentially inappropriate prescribing, primary 
health care 
 
Abbreviations: A&E (accident and emergency); ADEs (adverse drug events); BMQ (Beliefs 
about Medicine Questionnaire); CDSS (computerised decision support systems); CI 
(confidence interval); CME (continuing medical education); GP (general practitioner); HRB 
(Health Research Board); HRQOL (health related quality of life);  ICC (intraclass correlation 
coefficient); ICGP (Irish College of General Practitioners); IRR (incidence rate ratio); NSAID 
(Nonsteroidal anti-inflammatory drug); OR (odds ratio); PCRS (Primary Care Reimbursement 
Services); PIP (potentially inappropriate prescribing); QUB (Queen’s University Belfast; RCSI 
(Royal College of Surgeons in Ireland); RCT (randomised controlled trial); Rx-PAD 
(Prescription Peer Academic Detailing); TCA (Tricyclic Anti-depressant); WBQ-12 (Well-being 
Questionnaire) 
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INTRODUCTION  
Older people tend to have multimorbidity with consequent polypharmacy, making 
prescribing in this population challenging, with the potential for adverse outcomes including 
drug-drug interactions and adverse drug events (ADEs).1,2 Potentially inappropriate 
prescribing (PIP) describes a number of suboptimal prescribing practices particularly the use 
of medicines that introduce a greater risk of ADEs where a safer, as effective alternative is 
available to treat the same condition.3,4 PIP in older people is common across healthcare 
settings and can result in increased morbidity, ADEs and hospitalisations.2,5,6 In Ireland, 36% 
of those aged ≥70 years received at least one potentially inappropriate prescription in 2007, 
with an associated expenditure of over €45 million.7 PIP in community-dwelling older Irish 
people is associated with increased ADEs, accident and emergency (A&E) visits, and poorer 
health related quality of life (HRQOL).8  
 
Interventions targeting PIP represent an important public health measure, particularly in 
primary care where the majority of prescribing takes place. There is no one interventional 
strategy that has proved to be most effective.9 A number of commentators have argued that 
a multifaceted intervention, which combines a number of techniques within a single 
intervention,10 may be more likely to improve prescribing than any one single 
intervention.11,12 To date, a limited number of multifaceted interventions have been 
evaluated in primary care to decrease PIP.13,14  
 
The purpose of the OPTI-SCRIPT study (OPTImizing PreSCRIbing for Older People in Primary 
Care, a clusTer randomised controlled trial) was to investigate the effectiveness of a 
multifaceted intervention in reducing PIP in older people in Irish primary care.  
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METHODS 
A cluster randomised controlled trial (RCT) was conducted in Irish primary care to alter 
general practitioner (GP) PIP-related prescribing following the CONSORT guidelines.15 The 
study protocol and intervention development have been detailed previously.16,17 The 
Research Ethics Committee of the Irish College of General Practitioners (ICGP) approved the 
study.  
 
Recruitment and randomisation 
GP practices from the Health Research Board (HRB) Centre for Primary Care Research 
network were invited to participate by email with a follow-up phone call. Practices were 
eligible if they had at least 80 patients aged ≥ 70 years and were based in greater Dublin. 
Consenting practices were instructed to randomly select 50 patients aged ≥ 70 years with 
capacity to provide informed consent. Prescriptions of these patients were assigned a study 
ID and sent to the research team where the research pharmacist determined if they had PIP 
(Appendix 1).16  Eligible patients were sent study information packs by the GP practice and 
those wishing to participate returned signed consent forms to the research team.  
 
Baseline data were collected prior to allocation. Practices were allocated to intervention and 
control by an independent researcher using minimisation (Minimpy18), an allocation method 
commonly used in cluster RCTs to ensure balanced allocation of important cluster level 
attributes such as practice size when cluster numbers are small. It was not possible to blind 
patients or GPs to allocations, however, the outcome assessor was blinded.  
 
Intervention and control groups 
The multifaceted intervention involved academic detailing with a pharmacist on how to 
conduct GP-led medicines review with participating patients; medicines reviews were 
supported by web-based pharmaceutical treatment algorithms for GPs providing evidence-
based alternative treatment options to PIP drugs; and tailored patient information leaflets, 
(Table 1 and Appendix 2) 16 The intervention was delivered from October 2012 to 
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September 2013. Control practices delivered usual care and received one-off simple patient-
level PIP feedback (Table 1).  
 
Outcomes  
Outcome data were collected upon intervention completion (i.e. point at which all reviews 
were completed in a practice) at approximately 4-6 months following baseline data 
collection. 
 
Primary outcomes  
Two primary outcomes were used, firstly, the proportion of patients with PIP drugs (a 
composite measure, i.e. any number of PIP drugs as included in the study to address 
multiple PIP in individual patients). Secondly, the mean number of PIP drugs per group was 
investigated. PIP was determined for intervention and control groups from a review of 
prescriptions by a research pharmacist (Appendix 1).  
 
Secondary outcomes  
Secondary outcomes included individual measures of the composite measure, i.e. drug-
specific outcomes, including the absolute number of PIP drugs per group of the top five 
reported nationally:7 proton pump inhibitor at full therapeutic dosage for >8 weeks, long-
term (>3 months) use of non-steroidal anti-inflammatories (NSAIDs), long-term (>1 month) 
use of long-acting benzodiazepines, therapeutic duplication and  tricyclic antidepressants 
(TCAs) with an opiate or calcium channel blocker. Patient-reported outcomes included the 
Patients’ Beliefs about Medicines Questionnaire (BMQ),19 and the Well-being Questionnaire 
(WBQ-12)20 collected via self completed questionnaires. 
 
Sample size calculation  
A sample of at least 22 practices and 220 patients was required, incorporating the effects of 
cluster randomisation and a 10% loss to follow-up. The calculation was based on both 
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primary outcomes. The calculation for the proportion of participants with PIP was based on 
demonstrating a clinically relevant 10% absolute reduction (from 100% to 90%) in the 
proportion of PIP, with 80% power and a statistical significance of 5% (1-sided), between 
randomised groups. For the mean, the calculation was based on demonstrating a 30% 
relative reduction in the mean number of potentially inappropriate prescriptions in the 
intervention group compared to the control group (equivalent to a mean reduction of 1.02 
inappropriate prescriptions), with 80% power and a statistical significance of 5% (2-sided).17 
 
Analysis  
Data analysis was by intention to treat. 
 
Primary outcomes  
Separate approaches were used to analyse the two primary outcomes. The proportion of 
patients with PIP is presented and was analysed using a random effects logistic regression 
with the individual as the unit of analysis and the practice included as the random effect, to 
control for the effects of clustering. Baseline covariates (age, gender, baseline number of PIP 
drugs, baseline number of repeat medications) and minimisation factors (number of GPs, 
practice location) were included in the model.   
 
The mean number of PIP drugs was calculated per group, as specified in the study protocol, 
and a mean difference calculated using a cluster level t-test.17 However, preliminary 
analyses indicated that the data were skewed. The median number of PIP drugs was 
additionally investigated and skewness was addressed using a random effects Poisson 
regression, presenting incidence rate ratios (IRRs). Again, the individual was the unit of 
analysis and the practice was included as the random effect, and baseline covariates and 
minimisation factors were included.  The Bonferroni correction was used to adjust for 
multiple comparisons.   
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Secondary outcomes  
Random effects logistic regressions were used to test the differences in drug-specific 
secondary outcomes between intervention and control and random effects multiple 
regressions were conducted for the patient-reported outcomes. 
 
National contemporaneous comparison group 
The control group may have changed their prescribing behaviour due to the reactive effects 
of being studied (Hawthorne effect) and receiving simple feedback.21,22,23  In anticipation of 
this, anonymised data from the Primary Care Reimbursement Service (PCRS) pharmacy 
claims database of dispensed medications (national prescribing database of GP and 
pharmacy claims)24 were analysed, acting as a national contemporaneous comparison 
group. National PCRS prescribing data for those aged ≥ 70 years from September 2012 to 
August 2013, were analysed and the following data retrieved: 
1. Number of people with PIP 
2. Number of people with no PIP 
3. Decreases in the number of PIP drugs  
4. PIP that remained the same.  
PIP was assessed using  28 criteria included in this study,16 (six of the PIP criteria could not 
be applied as the PCRS data lacked the detailed information needed). 
From these figures, crude odds ratios (ORs) were calculated, comparing the OPTI-SCRIPT 
intervention and control groups to the national PCRS comparator. 
 
 
  
10 
 
 
RESULTS 
Figure 1 displays the flow of participants through the RCT. In total 21 GP practices and 196 
patients were recruited. All GP practices and 190 (97%) patients were followed up on 
intervention completion. Practices and patients were similar at baseline but the control 
group were situated in more socioeconomically deprived areas (Table 2). Proton pump 
inhibitors at maximum therapeutic dosage > 8 weeks was the most frequently occurring PIP 
in both groups (Table 3).  
 
Primary outcomes 
Upon intervention completion, the proportion of patients with PIP drugs was 0.52 in 
intervention compared to 0.77 in control. Participants in the intervention group had 
significantly lower odds of having PIP than those in the control group (adjusted OR 0.32, 
95% confidence interval (CI) 0.15 to 0.70, P=0.02) (Table 4). 
 
The mean number of PIP drugs in the intervention group was 0.70, compared to 1.18 in the 
control group (P=0.02).  The median was 1 in both intervention and control.  
Investigating the number of PIP drugs per person using Poisson regression, patients in the 
intervention group were estimated to have 29% less PIP drugs than patients in the control 
group, but this was not significant at the 5% level (IRR 0.71, 95% CI 0.50 to 1.02, P=0.49) 
(Table 4).  
 
Secondary outcomes  
Drug specific outcomes  
At intervention completion, participants in the intervention group had significantly lower 
odds of having a potentially inappropriate proton pump inhibitor compared to those in the 
control group (adjusted OR 0.30, 95% CI 0.14 to 0.68, P=0.04). No statistically significant 
differences were found for other drug-specific outcomes (Table 5).  In the intervention 
group, 50% of potentially inappropriate proton pump inhibitors were amended by dose 
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reduction to maintenance level, 20% were stopped completely, 11% were switched to an 
alternative (e.g. H2 antagonist) and 20% were unaltered.   
 
Patient reported outcomes  
For the patient reported outcomes of well-being and beliefs about medication, no 
statistically significant differences were found after completion of the intervention (Table 5).  
 
National contemporaneous comparison group 
Participants in the OPTI-SCRIPT intervention group had lower odds of having PIP compared 
to those in the national comparator group (crude OR 0.4, 95% CI 0.3 to 0.6) and were more 
likely to have a decrease in the number of PIP drugs, than the national comparator group 
(crude OR 2.5, 95% CI 1.8 to 4.0) (Table 6).  
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DISCUSSION  
The OPTI-SCRIPT intervention was effective in reducing PIP. However, this effect was 
mediated principally through reducing prescriptions of proton pump inhibitors at maximal 
dose, the most commonly encountered study PIP.  
 
Previous studies aimed at reducing PIP have been focused in hospital and nursing home 
settings.25-27 A limited number of RCTs to reduce PIP specifically in primary care have been 
conducted. Of those interventions that have been evaluated, single interventions such as 
computerised decision support systems (CDSSs), educational interventions and 
multidisciplinary teams have produced inconsistent effects.2,28,29 Multifaceted interventions 
may be more likely to improve prescribing than single interventions.11,12 
 
Our results are consistent with two separate RCTs published since the start of the OPTI-
SCRIPT study in finding a multifaceted intervention to be effective.13,14 Rognstad et al. found 
peer academic detailing, delivered at continuing medical education (CME) meetings, with 
mailed prescriber feedback, produced a 10% (95% CI 5.9 to 15.0) reduction in PIP in the Rx-
PAD study.14,30 Bregnhoj et al. found interactive educational meetings and feedback resulted 
in a 5-point (95% CI -7.3 to -2.6) improvement in the medication appropriateness index 
(MAI) score.13 Differences in effect sizes reported between these studies and the OPTI-
SCRIPT findings may arise from a number of factors including differences in the criteria used 
to assess PIP, the duration of follow-up and the included patients.  
An important difference may also be the intensity of the intervention. OPTI-SCRIPT was 
more intensive, delivering academic detailing face-to-face, rather than a group setting. 
During the medication reviews, GPs were provided directly with patient-specific lists of PIP 
drugs and advice on medication changes via the web-based pharmaceutical treatment 
algorithms, feasibly, having a larger effect size as it encouraged an immediate action to be 
taken rather than providing educational support or information.  
 
Changes in prescribing of particular drugs can be responsible for the overall effectiveness of 
interventions.31 The OPTI-SCRIPT intervention primarily impacted on proton pump inhibitors 
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prescribing which was highly prevalent at baseline (60%). No impact on therapeutic 
duplication or benzodiazepine use was found. This is likely due to the small numbers of 
patients exposed to these PIP drugs. However, this may also reflect the different challenges 
of modifying medicines as opposed to altering dosage regimes, particularly with 
benzodiazepines, whose tolerance levels result in interventions to improve prescribing 
having varying success.32 There is a concern that discontinuation of benzodiazepines in this 
population may produce more harm than benefit and patients may be reluctant 
discontinue.33,34 OPTI-SCRIPT GPs, may have been more comfortable altering proton pump 
inhibitors than benzodiazepines. Based on the low number of benzodiazepines in this study, 
we cannot be certain that the OPTI-SCRIPT intervention would be effective in reducing 
prescribing of these medications. 
 
The OPTI-SCRIPT intervention was not found to impact on patients’ sense of well-being and 
beliefs about medicine. The sample size may have been too small and the follow-up period 
too short to detect a difference in patient reported outcomes, a common criticism of 
prescribing  interventions.28 It is possible that beliefs about medicines may have been more 
likely to change than patients’ well-being given the short follow-up period, however, 
evidence indicates that beliefs about medicines remain stable over time, irrespective of 
changes in health status.35 Overall, these results suggest that modifications in proton pump 
inhibitors dosage do not appear to affect patient’s sense of well-being or concerns. 
 
Strengths and limitations  
Strengths of this study include a rigorous design of a clinically relevant intervention,16 high 
retention rates (primarily due to the nature of the outcome data and the short follow-up 
period), completeness of the prescription data and being conducted in a primary care 
setting using existing resources. Selection bias was minimised by collecting baseline data 
prior to minimisation, which was carried out by an independent third party. Owing to the 
nature of the intervention, it was not possible to blind patients or GPs to allocations, 
however, the outcome assessor was blinded to allocation,  
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The intervention was effective at decreasing the most prevalent PIP (proton pump 
inhibitors) in this study. The more frequent an outcome is, the greater the potential the OR 
will over or under estimate the relative risk (RR). Using methods proposed by Zhang et al36, 
we explored this and found little difference between the OR (0.32) and the RR (0.38), 
increasing confidence in the study findings. 
 
While the analysis of a non-randomised comparison group (PCRS data) provided a national 
context to the study, findings revealed no notable difference overall in prescribing 
behaviour by the control group compared to prescribing nationally, this is a non-randomised 
group and is therefore subject to confounding.  
 
The external validity of this study may have limitations. GP recruitment was modest at 32%, 
comparing favourably to similar PIP related RCTs 13 but smaller than reported in other 
primary care studies.37 When compared to a national sample of practices,38 study practices 
had, on average, more GPs and public patients so may not be representative of practices 
nationally. However, the last available national data on GPs was from 2005 so may be 
somewhat out of date.38  
 
Implications for practice and directions for future study  
The reduction in PIP in the OPTI-SCRIPT study may have important clinical and economic 
implications. Almost half of the intervention group were no longer exposed to PIP at 
intervention completion. While it cannot be assumed that a change in PIP necessitates a 
change in health outcomes,39,40 reducing PIP potentially may decrease adverse outcomes 
such as ADEs and hospitalisations in older patients.5 As the OPTI-SCRIPT study effect size 
was largely driven by proton pump inhibitor prescribing, the intervention may attenuate the 
risks associated with these drugs such as hip fractures and community acquired 
pneumonia.41,42  
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Reducing PIP related to proton pump inhibitor prescribing may also contribute to significant 
savings as an estimated €22 million was spent on potentially inappropriate proton pump 
inhibitors in 2007.43  
 
Based on the positive findings presented here, further modelling of the intervention 
components is planned to determine the effectiveness of the OPTI-SCRIPT intervention long 
term and the potential impact it may have on cases of PIP other than for proton pump 
inhibitor prescribing.  
 
PIP is an important public health concern that can result in increased morbidity, adverse 
drug events, hospitalisation and expenditure.2,7 This study shows that the OPTI-SCRIPT 
intervention reduced PIP, primarily through a reduction in proton pump inhibitor 
prescribing, in a way that this is acceptable to both GPs and their patients. Tailoring of the 
intervention to impact more specifically on different cases of PIP is planned. 
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Tables  
Table 1 Summary of OPTI-SCRIPT intervention and control groups 
Intervention The intervention consisted of: 
 
1) Academic detailing with a pharmacist 
One session (30 minutes) where  a pharmacist visited the practice to 
discuss PIP, medicines review and the web-based pharmaceutical 
treatment algorithms 
 
2) Medicines review with web-based pharmaceutical treatment algorithms. 
GPs were asked to conduct one review per patient using the web-based 
platform to guide them through the process. The GP was presented with 
the specific PIP drug(s) for each patient, and for each PIP drug, there was a 
treatment algorithm with the following structure: 
a. The individual PIP with reason for concern 
b. Alternative pharmacological and non-pharmacological 
treatment options 
c. Background information (where relevant) 
 
3) Patient information leaflets to give to patients during the review. Each 
leaflet: 
a. Described the PIP and the reasons as to why it may be 
inappropriate 
b. Outlined the alternative pharmacological and non-
pharmacological therapies GPs may offer. 
 
Control Control practices delivered usual care. Usual care for public general medical 
services (GMS) patients allows GPs to give a prescription on a monthly or three 
monthly basis.  
 
Control practices received simple patient-level PIP postal feedback in the form of 
a list summarizing the medication class to which the individual patient’s 
potentially inappropriate medication belonged.  
 
Control practices did not receive an academic detailing visit or were not 
prompted to carry out medicines review with the individual patients.  
Abbreviations: GMS (general medical services); PIP (potentially inappropriate prescribing)  
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Table 2 Baseline characteristics of practices and patients in intervention and control groups  
Characteristic Intervention  
N  
Control  
N  
Practice factors  
Number of practices (%) 11 (52.4) 10 (47.6) 
GMS list size (%) 
- 500 or less 
- 501- 1,500 
- 1,501 and over 
 
1 (9.1) 
3 (27.3) 
7 (63.6) 
 
2 (20.0) 
2 (20.0) 
6 (60.0) 
Practice with a manager 8 (72.8) 7 (70.0) 
Location (%) 
- Urban^ 
- Mixed 
 
8 (80.0) 
3 (20.0) 
 
8 (72.7) 
2 (27.3) 
Mean number of GPs per practice (SD) 4.1 (3.1) 4.1(2.1) 
Mean number of patients over 70 per practice 
(SD)  
712.1 (525.3) 788.2 (987.2) 
Median deprivation score† (IQR) 0.5 (-0.3 to 1.6) 1.4 (0.3 to 2.4) 
Patient factors 
Male (%) 55 (55.6) 50 (51.5) 
Marital status (%) 
- Married  
- Widowed  
- Single 
 
56 (56.6) 
26 (26.3) 
14 (14.1) 
 
51 (53.1) 
32 (33.3) 
10 (10.4) 
GMS card holder (SD) 88 (88.9) 95 (97.9) 
Mean age (SD) 77.1 (4.9) 76.4 (4.8) 
Mean number of repeat medications (SD) 10.2 (4.5) 9.5 (4.1) 
PIP* 
- Mean (SD) 
- Median (IQR) 
 
Most prevalent indicator: (%) 
- Proton Pump Inhibitors  
 
1.31 (0.6) 
1 (1 to 2) 
 
 
53 (53.3) 
 
1.39 (0.6) 
1 (1 to 2) 
 
 
65 (67.7) 
Figures are numbers (percentages) unless stated otherwise 
 
^ Urban area: relatively small centre of population, with 5,000 or more residents38 
† Population weighted deprivation score for each practice - large values mean practices are 
situated in more socio-economically deprived areas 
 
* All patients had at least one potentially inappropriate prescription at baseline  
 
Abbreviations: GMS (general medical services); IQR (Interquartile range);  
PIP (potentially inappropriate prescribing); SD (Standard Deviation)  
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Table 3 Potentially inappropriate prescriptions at baseline in intervention and control 
groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviatio
ns: NSAIDs (Nonsteroidal anti-inflammatory drug); TCAs (Tricyclic antidepressants); 
 
 
 
 
 
 
Potentially inappropriate prescription Intervention 
(N = 99) 
Control 
(N=97) 
N % N % 
Proton pump inhibitor at maximum 
therapeutic dosage for >8 weeks 
53 53.3 65 67.7 
NSAIDs  
Long terms use; interactions with certain medications 
e.g. diuretic  
21 21.2 16 16.8 
Therapeutic duplication 
Any regular duplicate drug class prescription, for 
example, two concurrent opiates, NSAIDs 
19 19.2 13 13.5 
Long-term (i.e. >1 month), long-acting 
benzodiazepines 
14 14.4 8 8.3 
Steroid without bisphosphonate  9 9.1 4 4.2 
Bladder antimuscarinics 
Contraindications and interactions with certain 
medications 
1 1.0 9 9.4 
Prolonged use (i.e. >1 week) of first-
generation antihistamines 
4 4.0 2 2.1 
Tricyclic antidepressants (TCAs)  
Contraindications and interactions with certain 
medications e.g. opiate, calcium channel 
blocker 
1 1.0 5 5.2 
Thiazide diuretic with gout 3 3.0 2 2.1 
Aspirin 
Contraindications and interactions with certain 
medications e.g. warfarin  
3 3.0 1 1.0 
Digoxin 
Inappropriate dose 
1 1.0 3 3.1 
Calcium channel blocker 
Contraindications and interactions with certain 
medications 
0 0.0 3 3.1 
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Table 4 Intention to treat analysis of primary outcomes at immediate intervention 
completion  
Characteristic Intervention 
N (%) 
Control 
N (%) 
Adjusted* 
odds ratio 
(95% CI) 
Adjusted* 
incident rate 
ratio 
(95% CI) 
Mean 
difference
***  
 (95% CI) 
P 
value 
Primary outcome: Proportion 
PIP at baseline  
PIP at intervention completion 
No PIP at intervention 
completion 
99 (100) 
52 (52.5) 
47 (47.5) 
97 (100) 
75 (77.3) 
22 (22.7) 
 
 
0.32  
(0.15 to 0.70) 
 
- 
 
- 
 
 
 
 
0.02 
Primary outcome: Mean 
Mean at baseline (SD) 
Mean at intervention 
completion (SD) 
1.31 (0.6) 
0.70 (0.1) 
 
1.39 (0.6) 
1.18 (0.1) 
 
- 
 
- 
 
- 0.48 
(-0.80 to -
0.17) 
 
0.02 
Additional outcome: Median  
Median at baseline (IQR) 
Median at intervention 
completion (IQR) 
1 (1 to 2) 
1 (0 to 1) 
1 (1 to 2) 
1 (1 to 2) 
 
- 
 
- 
 
- 
 
- 
 
Additional outcome: Poisson regression 
PIP at baseline  
PIP at intervention completion 
No PIP at intervention 
completion 
99 (100) 
52 (52.5) 
47 (47.5) 
97 (100) 
75 (77.3) 
22 (22.7) 
 0.71** 
(0.50 to 1.02) 
 0.49 
Figures are numbers (percentages) unless stated otherwise. The Bonferroni method was 
used to account for multiple comparisons. 
 
*Adjusted for age, gender, baseline number of PIP drugs, baseline number of repeat 
medications, number of GPs, practice location 
** Results from modelling the number of PIPs per person with Poisson regression adjusted 
for age, gender, baseline number of PIP drugs, baseline number of repeat medications, 
number of GPs, practice location 
*** Results from unadjusted cluster level t-test  
 
Abbreviations: CI (confidence interval); IQR (Interquartile range); PIP (potentially 
inappropriate prescribing); SD (Standard Deviation)  
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Table 5 Intention to treat analysis of secondary outcomes at immediate intervention 
completion  
Drug specific outcomes 
Characteristic Intervention  
N (%) 
Control  
N (%) 
Adjusted* odds 
ratio 
(95% CI) 
P value  
Proton pump inhibitor at baseline  
Proton pump inhibitor at intervention 
completion 
53 (53.5) 
23 (23.2) 
65 (67.7) 
46 (47.4) 
 
0.30 (0.14 to 0.68) 
 
0.04 
Duplicate at baseline 
Duplicate at intervention completion 
19 (19.2) 
11 (11.1) 
13 (13.5) 
11 (11.3) 
 
0.83 (0.32 to 2.13) 
 
0.99 
Long-term benzodiazepines at baseline 
Long-term benzodiazepines at 
intervention completion 
14 (14.1) 
9 (9.1) 
8 (8.1) 
9 (9.1) 
 
1.31 (0.47 to 3.68) 
 
 
0.99 
Figures are numbers (percentages) unless stated otherwise. The Bonferroni method was 
used to account for multiple comparisons. 
 
*Adjusted for age, gender, baseline number of PIP drugs, baseline number of repeat 
medications, number of GPs, practice location 
^Well-being Score ranges from 0-36 (1-12 low, 13-24 medium, 25-36 high)  
Ɨ Scale from -20-20 where positive scores indicate benefits outweigh risks  
 
Abbreviations: BMQ (Beliefs about Medicine Questionnaire); CI (confidence interval); WBQ-
12 (Well-being Questionnaire) 
  
Patient reported outcomes 
Characteristic Intervention Control Adjusted* mean 
difference (95% CI) 
P value 
WBQ: Mean well-being^ at baseline 
WBQ: Mean well-being^ at intervention 
completion 
24.3 
 
23.6 
24.4 
 
24.0 
 
  
- 0.41 (-1.80 to 1.07) 
 
 
0.99 
BMQ: Median necessity-concern 
differentialƗ  at baseline 
BMQ: Median necessity-concern 
differentialƗ  at baseline 
7.0 
 
 
6.0 
6.0 
 
 
5.8 
 
 
 
0.16 (-1.85 to 1.07) 
 
 
 
0.99 
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Table 6 Comparison of potentially inappropriate prescribing in the OPTI-SCRIPT study 
population to the national (PCRS) comparator 
Numbers (percentages) of participants are presented, unless otherwise stated  
PIP status OPTI-SCRIPT 
intervention 
group 
OPTI-SCRIPT 
control group 
PCRS national 
comparator 
Proportion with PIP 
PIP at baseline 99 (100) 97 (100) 103,261 (100) 
PIP at intervention completion 52 (52.5) 75 (77.3) 75,401 (73.1) 
No PIP at intervention 
completion 
47 (47.5) 22 (22.7) 27,860 (26.9) 
Crude odds ratio Ɨ 0.4 (95% CI 0.3 to 0.6) 
Decrease in PIP 
PIP at baseline 99 (100) 97 (100) 103,261 (100) 
PIP stayed same or increased 
at intervention completion 
42 (42.4) 65 (67.0) 67,188 (65.1) 
Decrease in PIP at 
intervention completion 
57 (57.6) 32 (32.9) 36,073 (34.9) 
Crude odds ratio Ɨ 2.5 (95% CI 1.8 to 4.0) 
Ɨ The odds of PIP in the OPTI-SCRIPT intervention group compared to the odds in national 
PCRS comparator data 
  
Abbreviations: CI (confidence interval); PCRS (primary care reimbursement services); PIP 
(potentially inappropriate prescribing); 
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Appendices  
Appendix 1:   Selected Prescribing Criteria/Prescribing Indicator 
Criteria Concern Prevalence in Ireland*  
PPI for peptic ulcer disease at full therapeutic 
dosage for >8 weeks  
Earlier discontinuation or dose 
reduction for maintenance/ 
prophylactic treatment of peptic 
ulcer disease, oesophagitis or 
GORD is indicated 
16.69%         
  
NSAID (>3 months) for relief of mild joint pain in 
osteoarthritis  
Simple analgesics are preferable 
and usually as effective for pain 
relief 
8.76%  
 
Long-term (i.e. >1 month), long-acting 
benzodiazepines, e.g. chlordiazepoxide, 
flurazepam, nitrazepam, chlorazepate and 
benzodiazepines with long-acting metabolites e.g. 
diazepam  
Risk of prolonged sedation, 
confusion, impaired balance, falls 
5.22%  
 
Any regular duplicate drug class prescription, e.g. 
2 concurrent opiates, NSAIDs, SSRIs, loop 
diuretics, ACE inhibitors. Excludes duplicate 
prescribing of drugs that may be required on a 
PRN basis, e.g. inhaled beta 2 agonists (long and 
short acting) for asthma or COPD, and opiates for 
management of breakthrough pain 
Optimization of monotherapy 
within a single drug class should be 
observed prior to considering a 
new class of drug 
4.78%                     
TCAs with an opiate or calcium channel blocker  Risk of severe constipation 2.05% 
Aspirin at dosage >150 mg/day Increased bleeding risk, no 
evidence for increased efficacy 
1.69%  
  
Theophylline as monotherapy for COPD/Asthma Risk of adverse effects due to 
narrow therapeutic index 
1.18%  
Use of aspirin and warfarin in combination 
without histamine H2 receptor antagonist (except 
cimetidine because of interaction with warfarin) 
or PPI 
High risk of GI bleeding 1.09%  
 
Doses of short-acting benzodiazepines, doses 
greater than: lorazepam (Ativan®), 3 mg; 
oxazepam (Serax®), 60 mg; alprazolam (Xanax®), 2 
mg; temazepam (Restoril®), 15 mg; and triazolam 
(Halcion®), 0.25 mg 
Total daily doses should rarely 
exceed the suggested maximums 
1.54%  
Prolonged use (>1 week) of first generation 
antihistamines, i.e. diphenydramine, 
chlorpheniramine, cyclizine, promethazine  
Risk of sedation and anticholinergic 
side-effects 
0.96%                    
Warfarin and NSAID together  Risk of GI bleeding 0.75%                     
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Calcium channel blockers with chronic 
constipation 
May exacerbate constipation 0.68%                   
 
NSAID with history of peptic ulcer disease or GI 
bleeding, unless with concurrent histamine H2 
receptor antagonist, PPI or misoprostol  
Risk of peptic ulcer relapse 0.67%                
Bladder antimuscarinic drugs with dementia  Risk of increased confusion, 
agitation 
0.46%           
TCAs with constipation  May worsen constipation 0.45%                                
Digoxin at a long-term dosage >125 µg/day (with 
impaired renal function) 
Increased risk of toxicity 0.36%                    
 
Thiazide diuretic with a history of gout                                                                           May exacerbate gout 0.36%        
 
Glibenclamide (with type 2 diabetes mellitus)  Risk of prolonged hypoglycaemia 0.29%                      
Aspirin with a past history of peptic ulcer disease, 
without histamine H2 receptor antagonist or PPI 
Risk of bleeding 0.22%                    
 
Prochlorperazine (Stemetil®) or metoclopramide 
with Parkinsonism  
Risk of exacerbating Parkinsonism 0.21%    
TCAs with dementia  Risk of worsening cognitive 
impairment 
0.18%           
 
TCAs with glaucoma  Likely to exacerbate glaucoma 0.14%  
TCAs with cardiac conductive abnormalities  Pro-arrhythmic effects 0.14%  
Long-term corticosteroids (>3 months) as 
monotherapy for rheumatoid arthritis or 
osteoarthritis  
Risk of major systemic 
corticosteroid side-effects 
0.14%  
Bladder antimuscarinic drugs with chronic 
prostatism  
Risk of urinary retention 0.14%  
NSAID with heart failure Risk of exacerbation of heart failure 0.07%   
TCAs with prostatism or prior history of urinary 
retention  
Risk of urinary retention 0.07%                     
 
Systemic corticosteroids instead of inhaled 
corticosteroids for maintenance therapy in 
COPD/Asthma 
Unnecessary exposure to long-term 
side-effects of systemic steroids 
0.07%                    
 
Bladder antimuscarinic drugs with chronic 
glaucoma  
Risk of acute exacerbation of 
glaucoma 
<0.01%              
NSAID with SSRI Increased risk of GI bleeding   N/A 
Bladder antimuscarinic drugs with chronic Risk of exacerbation of constipation  N/A 
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constipation  
Prednisolone (or equivalent) >  3 months or longer 
without bisphosphonate 
Increased risk of fracture  N/A 
NSAID with ACE-inhibitor Risk of kidney failure, particularly 
with the presence of general 
arteriosclerosis, dehydration or 
concurrent use of diuretics 
 N/A 
NSAID with diuretic May reduce the effect of diuretics 
and worsen existing heart failure 
 N/A 
Abbreviations – ACEI (angiotensin-converting-enzyme inhibitor); COPD (chronic obstructive pulmonary disease); GI (gastro-
intestinal); NA (not available); GORD (gastro-oesophageal reflux disease); NSAID (Nonsteroidal anti-inflammatory drug); PPI 
(Proton Pump Inhibitor); PRN (Pro re nata, as needed); SSRI (Selective serotonin reuptake inhibitor); TCA (Tricyclic Anti-
depressant) 
 
*Prevalence – the proportion of the study population with 1 or more potentially inappropriate medications  
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Appendix 2 OPTI-SCRIPT Website materials 
 
Table A2.1 OPTI-SCRIPT treatment algorithm example  
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Table A2.1 OPTI-SCRIPT patient information leaflet  
 
 
 
 
 
 
 
